Research letterBrodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed
References (4)
- et al.
Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents
J Am Acad Dermatol
(2019) - et al.
Psoriasis: which therapy for which patient: focus on special populations and chronic infections
J Am Acad Dermatol
(2019)
Cited by (37)
Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors
2021, Journal of the American Academy of DermatologyEfficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis
2021, Journal of the American Academy of DermatologyCitation Excerpt :Forty-seven studies were full-text reviewed; 14 unique studies were included comprising 655 patients with psoriasis (Supplemental Fig 1; available via Mendeley at https://doi.org/10.17632/5z29m63xpz.1).17,35-46 One study reported on only secukinumab,35 10 studies reported on only ixekizumab,17,36-44 2 studies reported on only brodalumab,45,46 and 1 study reported on all treatments47 (Supplemental Table I; available via Mendeley at https://doi.org/10.17632/5z29m63xpz.1). Four studies reported the time between switches, 3 reported on the minimum washout period between switches, and 7 reported no information on the time between switches.
Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)
2024, Journal of the European Academy of Dermatology and VenereologyDrug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis over up to 3 years
2024, International Journal of DermatologyBrodalumab is an Efficacious, Safe, and Cost-Effective IL-17 Receptor Blocker for the Treatment of Moderate-to-Severe Plaque Psoriasis: 2023 Update
2023, Journal of Drugs in Dermatology
Funding sources: This study received funding from Ortho Dermatologics.
Conflicts of interest: Dr Kimmel participated on an advisory board for Ortho Dermatologics, October 2018. Dr Chima is a consultant for Leo Pharma. Dr Bagel is an investigator, speaker, or advisory board for LEO, Abbvie, Amgen, Eli-Lilly, Novartis, Celgene, Janssen, Boehringer Ingelheim, BMS, and UCB. Dr Lebwohl receives research funds from Abbvie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Corrona, Inc, Eli Lilly, Foundation for Research & Education in Dermatology, Incyte, Janssen Research & Development, LLC,Kadmon Corp, LLC, Leo Pharmaceuticals, MedImmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm, UCB, Inc, and ViDac and is a consultant for Allergan, Almirall, Arcutis Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Leo Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, and Verrica. Drs H. Kim, Bares, and S. Kim, and Christopher J. Yao, and Giselle Singer have no conflicts of interest to declare.